Streptococcus mitis (S. mitis)

Streptococcus mitis is a species of Gram-positive, alpha‑hemolytic cocci belonging to the viridans group streptococci. It is a facultative anaerobe that commonly inhabits the human mouth and upper respiratory tract as part of the normal oral microbiota[5]. While generally considered non-pathogenic in healthy individuals, it can act as an opportunistic pathogen—most notably causing infective endocarditis, especially in immunocompromised patients or those with prosthetic heart valves[4][7]. S. mitis is biochemically characterized by being catalase-negative and oxidase-positive; it does not form spores or capsules and grows best on blood agar under facultative anaerobic conditions[1][6]. S. mitis has been studied for its role in biofilm formation and interspecies interactions within polymicrobial communities; for example, its production of autoinducer‑2 (AI‑2) can promote pathogenicity when co-cultured with Pseudomonas aeruginosa—a mechanism that may be targeted to inhibit biofilm-associated infections such as ventilator-associated pneumonia[2][3]. Treatment typically involves beta-lactam antibiotics like penicillin or ampicillin; however, increasing rates of resistance have been reported against several antibiotic classes including macrolides and lincosamides[8]. Note: Streptococcus mitis is not a molecular target such as a receptor or enzyme but rather an entire bacterial species. Therefore, - is_target: false — it is not considered a therapeutic target molecule/receptor. - is_incorrect: true — because "Streptococcus mitis" refers to an organism rather than a specific molecular drug target. If you are seeking information about targeting molecules produced by S. mitis—such as AI‑2 quorum sensing signals—please specify further so structured data can be provided for those molecular targets instead[2][3].

Other names

Streptococcus mitiorViridans streptococcus (group)SMG (Streptococcus mitis group)

Inhibition of cell wall synthesis (beta-lactams like penicillin/ampicillin)